Earnings Feed
Start Free
Home/Filings/4/0001104659-15-068866
4//SEC Filing

KYTHERA BIOPHARMACEUTICALS INC 4

Accession 0001104659-15-068866

CIK 0001436304operating
View on SEC.govCompany Profile

Filed

Oct 1, 8:00 PM ET

Accepted

Oct 2, 2:19 PM ET

Size

18.0 KB

Accession

0001104659-15-068866

Insider Transaction Report

Form 4
Period: 2015-10-01
KYTHERA BIOPHARMACEUTICALS INCKYTH
David Nathaniel E
Director
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−5,672→ 0 total
    Exercise: $16.00Exp: 2022-10-10→ Common Stock (5,672 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−1,512→ 0 total
    Exercise: $4.84Exp: 2019-01-21→ Common Stock (1,512 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−8,400→ 0 total
    Exercise: $33.26Exp: 2024-06-05→ Common Stock (8,400 underlying)
  • Disposition to Issuer

    Common Stock

    2015-10-01−429,874→ 0 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−9,832→ 0 total
    Exercise: $4.84Exp: 2019-09-17→ Common Stock (9,832 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−6,618→ 0 total
    Exercise: $21.65Exp: 2023-06-04→ Common Stock (6,618 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−11,591→ 0 total
    Exercise: $53.26Exp: 2025-06-02→ Common Stock (11,591 underlying)
Footnotes (3)
  • [F1]Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015 (the "Merger Agreement"), by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby each share of Issuer common stock was canceled in exchange for $75.00 in cash, without interest.
  • [F2]Reflects a transfer of 30,286 shares exempt under Section 16a-12 since the Reporting Person's last ownership report.
  • [F3]Pursuant to the Merger Agreement, each option to purchase common stock was canceled and paid in cash assuming a stock price of $75.00.

Documents

1 file

Issuer

KYTHERA BIOPHARMACEUTICALS INC

CIK 0001436304

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001436304

Filing Metadata

Form type
4
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 2:19 PM ET
Size
18.0 KB
View on SEC.gov